The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT ID: NCT01195805
Last Updated: 2015-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2010-08-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Amiloride and Spironolactone in Healthy Persons
NCT00857909
The Effect of Amiloride and Spironolactone in Patients With Hypertension
NCT01388088
Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension
NCT00709137
Double Blind Crossover Comparison of Diuretics in the Young
NCT00429897
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
NCT01314898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Renal function (GFR, u-AQP2, u-ENaCĪ², u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsewave velocity, augmentation index central bloodpressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory bloodpressure
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amiloride
Amiloride
1 tablet twice a day for 28 days
Spironolactone
Spironolactone
1 tablet twice a day for 28 days
Placebo
1 tablet twice a day for 28 days
Placebo
1 tablet twice a day for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone
1 tablet twice a day for 28 days
Placebo
1 tablet twice a day for 28 days
Amiloride
1 tablet twice a day for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 18,5-30,
* non-smoker
Exclusion Criteria
* Not using contraceptives
* Other illnesses
* Drug or alcohol abuse
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erling Bjerregaard Pedersen
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Solveig K Matthesen, MD
Role: PRINCIPAL_INVESTIGATOR
Departments of medical research and medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Departments of medical research and medicine
Holstebro, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED.RES.HOS.2010.03.SKM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.